Bandhan Healthcare Fund - Regular Plan - Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 10-11-2025
AUM:
319.4 Cr
Expense Ratio
2.75%
Benchmark
BSE Healthcare TRI
ISIN
INF194KB1KC2
Minimum Investment
1000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Viraj Kulkarni, Brijesh Shah, Ritika Behera, Gaurav Satra
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Bandhan Healthcare Fund - Regular Plan - Growth | - | - | - |
| Benchmark | - | - | - |
If you invested in this fund:
₹
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
11.237
Last change
-0.01 (-0.0712%)
Fund Size (AUM)
₹ 319.4 Cr
Performance
12.87% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors. Disclaimer: There is no assurance or guarantee that the scheme’s objectives will be realised.
Fund Manager
Viraj Kulkarni, Brijesh Shah, Ritika Behera, Gaurav Satra
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 10.11 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 8.08 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 6.82 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 6.3 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 6.12 |
| JB Chemicals & Pharmaceuticals Limited | 4.27 |
| Dr. Reddys Laboratories Ltd | 4.21 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 3.92 |
| GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/- | 3.42 |
| DR. LAL PATHLABS LIMITED EQ NEW FV RS. 10/- | 2.96 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 93.97 |
| Financial Services | 2.48 |
| Information Technology | 0.26 |